S&P 500   3,870.29
DOW   31,391.52
QQQ   318.40
S&P 500   3,870.29
DOW   31,391.52
QQQ   318.40
S&P 500   3,870.29
DOW   31,391.52
QQQ   318.40
S&P 500   3,870.29
DOW   31,391.52
QQQ   318.40
Log in

Gritstone Oncology Stock Forecast, Price & News

+0.89 (+6.32 %)
(As of 03/2/2021 12:00 AM ET)
Today's Range
Now: $14.97
50-Day Range
MA: $15.41
52-Week Range
Now: $14.97
Volume1.15 million shs
Average Volume4.68 million shs
Market Capitalization$565.33 million
P/E RatioN/A
Dividend YieldN/A
Gritstone Oncology, Inc., a clinical-stage biotechnology company, engages in developing tumor-specific cancer immunotherapies to fight various cancer types and infectious diseases. Its lead product candidate is GRANITE, which is in Phase I/II clinical trial for the treatment of solid tumors, including metastatic non-small cell lung cancer, as well as gastroesophageal, bladder and microsatellite stable, and colorectal cancers. The company is also developing SLATE, an off-the-shelf immunotherapy candidate which is in Phase I/II clinical study for the treatment of common solid tumors, including metastatic non-small cell lung cancer, colorectal cancer, pancreatic cancer, and other mutation-positive tumors. Gritstone Oncology, Inc. has a strategic collaboration with bluebird bio, Inc. The company was founded in 2015 and is headquartered in Emeryville, California.
Gritstone Oncology logo

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Current SymbolNASDAQ:GRTS
Year FoundedN/A



Sales & Book Value

Annual Sales$4.36 million
Book Value$3.75 per share


Net Income$-94,430,000.00
Net Margins-2,962.52%


Market Cap$565.33 million
Next Earnings Date3/10/2021 (Estimated)
OptionableNot Optionable


Overall MarketRank

1.63 out of 5 stars

Medical Sector

292nd out of 1,969 stocks

Biological Products, Except Diagnostic Industry

35th out of 177 stocks

Analyst Opinion: 3.2Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -
+0.89 (+6.32 %)
(As of 03/2/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive GRTS News and Ratings via Email

Sign-up to receive the latest news and ratings for GRTS and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Gritstone Oncology (NASDAQ:GRTS) Frequently Asked Questions

Is Gritstone Oncology a buy right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Gritstone Oncology in the last year. There are currently 1 sell rating and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" Gritstone Oncology stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in GRTS, but not buy additional shares or sell existing shares.
View analyst ratings for Gritstone Oncology
or view top-rated stocks.

What stocks does MarketBeat like better than Gritstone Oncology?

Wall Street analysts have given Gritstone Oncology a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Gritstone Oncology wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Gritstone Oncology?

Gritstone Oncology saw a increase in short interest during the month of February. As of February 12th, there was short interest totaling 2,840,000 shares, an increase of 123.6% from the January 28th total of 1,270,000 shares. Based on an average daily volume of 3,050,000 shares, the days-to-cover ratio is currently 0.9 days. Currently, 8.4% of the shares of the company are short sold.
View Gritstone Oncology's Short Interest

When is Gritstone Oncology's next earnings date?

Gritstone Oncology is scheduled to release its next quarterly earnings announcement on Wednesday, March 10th 2021.
View our earnings forecast for Gritstone Oncology

How were Gritstone Oncology's earnings last quarter?

Gritstone Oncology, Inc. (NASDAQ:GRTS) posted its earnings results on Thursday, November, 5th. The company reported ($0.69) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.64) by $0.05. The firm earned $0.94 million during the quarter, compared to analysts' expectations of $1.20 million. Gritstone Oncology had a negative net margin of 2,962.52% and a negative trailing twelve-month return on equity of 101.31%.
View Gritstone Oncology's earnings history

How has Gritstone Oncology's stock been impacted by Coronavirus?

Gritstone Oncology's stock was trading at $6.67 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, GRTS shares have increased by 124.4% and is now trading at $14.97.
View which stocks have been most impacted by COVID-19

What price target have analysts set for GRTS?

3 equities research analysts have issued 1 year price objectives for Gritstone Oncology's shares. Their forecasts range from $8.00 to $35.00. On average, they expect Gritstone Oncology's stock price to reach $22.33 in the next year. This suggests a possible upside of 49.2% from the stock's current price.
View analysts' price targets for Gritstone Oncology
or view top-rated stocks among Wall Street analysts.

Who are Gritstone Oncology's key executives?

Gritstone Oncology's management team includes the following people:
  • Dr. Andrew R. Allen, Co-Founder, Pres, CEO, Interim Principal Financial Officer & Director (Age 54, Pay $792.27k)
  • Dr. Karin Jooss, Exec. VP of Research & Chief Scientific Officer (Age 56, Pay $570.87k)
  • Prof. Raphael F. Rousseau M.D., Ph.D., Exec. VP & Chief Medical Officer (Age 52, Pay $588.37k)
  • Mr. James Cho, VP of Fin. & Principal Accounting Officer
  • Dr. Roman Yelensky, Exec. VP & CTO (Age 42)
  • Mr. Rahsaan W. Thompson J.D., Exec. VP & Gen. Counsel (Age 49)
  • Mr. Matthew Hawryluk, Exec. VP & Chief Bus. Officer (Age 43)
  • Mr. Erin E. Jones M.S., Exec. VP of Global Regulatory Affairs & Quality (Age 49)
  • Mr. Vijay Yabannavar Ph.D., Exec. VP of Manufacturing & Technical Operations (Age 60)
  • Mr. Alan C. Mendelson J.D., Sec. (Age 71)

What is Andrew Allen's approval rating as Gritstone Oncology's CEO?

1 employees have rated Gritstone Oncology CEO Andrew Allen on Glassdoor.com. Andrew Allen has an approval rating of 100% among Gritstone Oncology's employees. This puts Andrew Allen in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Gritstone Oncology's key competitors?

What other stocks do shareholders of Gritstone Oncology own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Gritstone Oncology investors own include ADMA Biologics (ADMA), Bionano Genomics (BNGO), Matinas BioPharma (MTNB), Novan (NOVN), Sorrento Therapeutics (SRNE), Zosano Pharma (ZSAN), Enerplus (ERF), Oncolytics Biotech (ONCY), SCYNEXIS (SCYX) and CBL & Associates Properties (CBL).

When did Gritstone Oncology IPO?

(GRTS) raised $85 million in an initial public offering on Friday, September 28th 2018. The company issued 6,100,000 shares at $13.00-$15.00 per share. Goldman Sachs, Cowen and Barclays served as the underwriters for the IPO and BTIG was co-manager.

What is Gritstone Oncology's stock symbol?

Gritstone Oncology trades on the NASDAQ under the ticker symbol "GRTS."

Who are Gritstone Oncology's major shareholders?

Gritstone Oncology's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Avidity Partners Management LP (5.62%), BlackRock Inc. (5.20%), Northern Trust Corp (0.79%), Renaissance Technologies LLC (0.67%), JPMorgan Chase & Co. (0.46%) and Nuveen Asset Management LLC (0.42%).
View institutional ownership trends for Gritstone Oncology

Which major investors are selling Gritstone Oncology stock?

GRTS stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Russell Investments Group Ltd., Renaissance Technologies LLC, Walleye Capital LLC, Walleye Trading LLC, Captrust Financial Advisors, Northern Trust Corp, and JPMorgan Chase & Co..
View insider buying and selling activity for Gritstone Oncology
or view top insider-selling stocks.

Which major investors are buying Gritstone Oncology stock?

GRTS stock was acquired by a variety of institutional investors in the last quarter, including Avidity Partners Management LP, SkyOak Wealth LLC, Squarepoint Ops LLC, ExodusPoint Capital Management LP, Wells Fargo & Company MN, Rhumbline Advisers, Raymond James Financial Services Advisors Inc., and Citigroup Inc..
View insider buying and selling activity for Gritstone Oncology
or or view top insider-buying stocks.

How do I buy shares of Gritstone Oncology?

Shares of GRTS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Gritstone Oncology's stock price today?

One share of GRTS stock can currently be purchased for approximately $14.97.

How much money does Gritstone Oncology make?

Gritstone Oncology has a market capitalization of $565.33 million and generates $4.36 million in revenue each year. The company earns $-94,430,000.00 in net income (profit) each year or ($2.81) on an earnings per share basis.

How many employees does Gritstone Oncology have?

Gritstone Oncology employs 177 workers across the globe.

What is Gritstone Oncology's official website?

The official website for Gritstone Oncology is www.gritstoneoncology.com.

Where are Gritstone Oncology's headquarters?

Gritstone Oncology is headquartered at 5858 HORTON STREET SUITE 210, EMERYVILLE CA, 94608.

How can I contact Gritstone Oncology?

Gritstone Oncology's mailing address is 5858 HORTON STREET SUITE 210, EMERYVILLE CA, 94608. The company can be reached via phone at 510-871-6100 or via email at [email protected]

This page was last updated on 3/3/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.